A Commentary on the role of governments in mitigating the health effects of malnutrition, in the context of SDGs 3 and 12, highlighting the need for the implementation of more comprehensive policies to limit the availability of unhealthy foods and to increase that of healthy foods to communities across Africa.
Background: The COVID-19 pandemic has affected mental health, psychological wellbeing, and social interactions.
Elsevier,
Emerging Programs for Autism Spectrum Disorder Improving Communication, Behavior, and Family Dynamics 2021, Pages 243-264
This book chapter advances SDG3 Good Health and Wellbeing and SDG 10 Reducing Inequalities by reviewing a pilot rehabilitation program for children with a combination of intellectual/autism spectrum disorder and motor disorders.
This book chapter advances SDG 3 and 10 by discussing the importance of social support and psychological flexibility to act as a buffer between the effects of COVID-19 on psychological distress and mental health.
This book chapter advances SDG 3 and 10 reviewing the extent to which coronavirus lockdown and restrictions have affected the life of the people of Ghana
This book chapter advances SDG 3 and 10 by exploring the gap within research literature in which the intersectional complexities of South Asian Muslims lie by examining the historical and geopolitical contexts of South Asian Muslim experiences in the United States. This chapter discusses the ways in which contemporary South Asian Muslim American experiences are further complicated when navigating additional marginalized identities such as gender and sexual orientation, age and generational influences, disability status, class, and national origin.
Background: Viral hepatitis could have an impact on the treatment response in HIV patients.
The pharmacologic parameters that drive optimal HIV latency reversal in vivo are unknown and could be influenced by such factors as the HDACi binding kinetics, concentration of compound, and duration of exposure. This study evaluates how these parameters affect HIV latency reversal for a series of novel HDACis that differ in their enzymatic on and off rates. The comprehensive data set generated by automating the assays described here was used to establish a PK/PD model for HDACi-induced HIV latency reversal.
Collaborative efforts between public and private entities such as academic institutions, governments, and pharmaceutical companies form an integral part of scientific research, and notable instances of such initiatives have been created within the life science community. Several examples of alliances exist with the broad goal of collaborating toward scientific advancement and improved public welfare. Such collaborations can be essential in catalyzing breaking areas of science within high-risk or global public health strategies that may have otherwise not progressed. A common term used to describe these alliances is public-private partnership (PPP). This review discusses different aspects of such partnerships in drug discovery/development and provides example applications as well as successful case studies. Specific areas that are covered include PPPs for sharing compounds at various phases of the drug discovery process—from compound collections for hit identification to sharing clinical candidates. Instances of PPPs to support better data integration and build better machine learning models are also discussed. The review also provides examples of PPPs that address the gap in knowledge or resources among involved parties and advance drug discovery, especially in disease areas with unfulfilled and/or social needs, like neurological disorders, cancer, and neglected and rare diseases.
